FLT3 and neoplasm: Even more profound responses were found in MOLM-16 (FLT3-WT) tumor-bearing SCID/beige mice: ~100% TGI was reached at doses 50 mg/kg in QD schedule and 25 mg/kg in BID schedule (Figure 4A).